Literature DB >> 28761995

Intermediate term thrombotic risk in contemporary total cavo-pulmonary connection for single ventricle circulations.

Jenna M Faircloth1, Olivia Roe2, Tarek Alsaied3, Joseph S Palumbo4, Alexander Vinks5, Gruschen R Veldtman6.   

Abstract

Despite the common occurrence of thrombosis in Fontan circulations, the mid-term thrombotic risk beyond the first two postoperative years is poorly defined especially in total cavo pulmonary Fontan. This study examines the thrombotic incidence and risk beyond the first 2 years after contemporary Fontan surgery. Using a retrospective cohort study design, 89 Fontan patients, 50 male, were included and evaluated with a median of 8.3 years (IQR 6.8-11.4) follow-up. Hospital records were reviewed for known risk factors of thrombosis, thrombotic events, antiplatelet and anticoagulation management, and basic characteristics. Forty seven patients (52%) had a dominant left ventricle, and 28 (32%) had hypoplastic left heart syndrome. Eight patients had thrombotic events post Fontan surgery at a median age of 9 years (IQR 5.6-13), 5.7 (IQR 2.0-9.7) years following surgery, not including events that occurred immediately peri-operatively. Four thrombotic events were intracardiac whereas the remainder were extra-cardiac. There was no significant univariate correlation between thrombosis and the presence of ventricular morphology, pulmonary arterial reconstruction, or type of cavopulmonary anastomosis (lateral tunnel vs. extracardiac conduit). Thrombosis continues to be an important intermediate-term risk even for patients with contemporary Fontan circulations. These results strongly suggest that thrombophilic risk is not dictated purely by vascular pathway and hemodynamic variables. Further investigation into the pathophysiology, individualized risk, and effectiveness of anticoagulation strategies are required in this high risk population.

Entities:  

Keywords:  Anticoagulation; Coagulation; Fontan; Single ventricle; Thrombosis

Mesh:

Substances:

Year:  2017        PMID: 28761995     DOI: 10.1007/s11239-017-1530-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  18 in total

1.  Evaluation of hemostatic and coagulation factor abnormalities in patients undergoing the Fontan operation.

Authors:  M Jahangiri; J Kreutzer; D Zurakowski; E Bacha; R A Jonas
Journal:  J Thorac Cardiovasc Surg       Date:  2000-10       Impact factor: 5.209

2.  Thromboembolic complications after fontan procedures--the role of prophylactic anticoagulation.

Authors:  P Monagle; A Cochrane; B McCrindle; L Benson; W Williams; M Andrew
Journal:  J Thorac Cardiovasc Surg       Date:  1998-03       Impact factor: 5.209

3.  Estimation in Markov models from aggregate data.

Authors:  J D Kalbfleisch; J F Lawless; W M Vollmer
Journal:  Biometrics       Date:  1983-12       Impact factor: 2.571

4.  A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children.

Authors:  Paul Monagle; Andrew Cochrane; Robin Roberts; Cedric Manlhiot; Robert Weintraub; Barbara Szechtman; Marina Hughes; Maureen Andrew; Brian W McCrindle
Journal:  J Am Coll Cardiol       Date:  2011-08-02       Impact factor: 24.094

5.  Thrombus formation after the Fontan operation.

Authors:  P D Coon; J Rychik; R T Novello; P S Ro; J W Gaynor; T L Spray
Journal:  Ann Thorac Surg       Date:  2001-06       Impact factor: 4.330

6.  Aspirin resistance in adult patients after Fontan surgery.

Authors:  Lidia Tomkiewicz-Pajak; Tomasz Wojcik; Stefan Chłopicki; Maria Olszowska; Jacek Pajak; Jakub Podolec; Barbara Sitek; Piotr Musiałek; Paweł Rubis; Monika Komar; Piotr Podolec
Journal:  Int J Cardiol       Date:  2014-11-27       Impact factor: 4.164

7.  Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: increased factor VIII may predispose to thrombosis.

Authors:  Kirsten C Odegard; Francis X McGowan; David Zurakowski; James A Dinardo; Robert A Castro; Pedro J del Nido; Peter C Laussen
Journal:  J Thorac Cardiovasc Surg       Date:  2003-06       Impact factor: 5.209

8.  Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure.

Authors:  Brian W McCrindle; Cedric Manlhiot; Andrew Cochrane; Robin Roberts; Marina Hughes; Barbara Szechtman; Robert Weintraub; Maureen Andrew; Paul Monagle
Journal:  J Am Coll Cardiol       Date:  2012-12-12       Impact factor: 24.094

Review 9.  Fontan circulation: success or failure?

Authors:  Blandine Mondésert; François Marcotte; François-Pierre Mongeon; Annie Dore; Lise-Andrée Mercier; Reda Ibrahim; Anita Asgar; Joaquim Miro; Nancy Poirier; Paul Khairy
Journal:  Can J Cardiol       Date:  2013-03-06       Impact factor: 5.223

10.  Altered endothelial function following the Fontan procedure.

Authors:  Maria A Binotto; Nair Y Maeda; Antonio A Lopes
Journal:  Cardiol Young       Date:  2007-12-20       Impact factor: 1.093

View more
  2 in total

Review 1.  A Narrative Review of Postoperative Anticoagulation Therapy for Congenital Cardiac Disease.

Authors:  Alexander A Boucher; Julia A Heneghan; Subin Jang; Kaitlyn A Spillane; Aaron M Abarbanell; Marie E Steiner; Andrew D Meyer
Journal:  Front Surg       Date:  2022-06-14

2.  Increased Risk for Thromboembolism After Fontan Surgery: Considerations for Thromboprophylaxis.

Authors:  Suelyn Van Den Helm; Christopher Noel Sparks; Vera Ignjatovic; Paul Monagle; Chantal Attard
Journal:  Front Pediatr       Date:  2022-03-28       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.